COMPARING The EFFICACY AND SAFETY OF TREATMENT WITH FIXED DOSE OF TADALAFIL OR TAMSULOSIN AND THEIR COMBINATION THERAPY IN Patients With BENIGN PROSTATIC HYPERPLASIA and Erectile Dysfunction
Abstract
Abstract Purpose To compare monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia and erectile dysfunction by comparing IPSS score, prostate volume and Qmax and some other outcomes. Materials and Methods All patients with lower urinary tract symptoms, benign prostatic hyperplasia and any grade of erectile dysfunction were recruited. They were randomly divided into three groups (50 participants in each group): Group A received 5 mg/daily tadalafil; Group B received 0.4 mg/daily tamsulosin; Group C receieved a combination of 0.4 mg/daily tamsulosin and 5 mg/daily tadalafil. Primary outcomes were prostate volume, prostate specific antigen, post-void residual volume, IPSS score, LUTS severity, Qmax, IIEF and erectile dysfunction severity and secondary outcome was complications. Results The mean ± SD of ultrasonographic prostate volume was 61.4 ± 15.1 mL and prostate specific antigen level was 2.4 ± 1.9 ng/dl. Post-void residual level was significantly different before and after the treatment, except for group A. Also, this group had no meaningful difference compared to the other groups in this regard (P > 0.05). There were significant differences between pre- and post-treatment international prostate symptom scores in each group (P < 0.05). Conclusion: Combination of tamsulosin and tadalafil can improve international prostate symptom scores, international index of erectile function questionnaire scores and Qmax in…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.